Jenyfer María Fuentes‐MendozaJuan Manuel Muñoz MorenoMarcio José Concepción‐ZavaletaLuis Alberto Concepción‐UrteagaJosé Paz‐IbarraRoger Gonzales‐ValdiviesoFernanda Ginebra Castillo‐VelásquezAngie Sofía Burgos‐CastilloRegina Garza‐BoullosaVanesa Daniela Núñez‐Pérez2026-03-222026-03-22202510.1111/eci.70101https://doi.org/10.1111/eci.70101https://andeanlibrary.org/handle/123456789/85959SC- and BAT-based therapies offer innovative avenues for repairing damaged myocardium. Their application could revolutionise treatment strategies for heart failure and post-infarction remodelling. However, clinical translation requires addressing immune compatibility, arrhythmic risk and manufacturing limitations. Interdisciplinary collaboration and regulatory standardisation are essential for their future clinical adoption.enDecellularizationRegenerative medicineStem cellTissue engineeringMedicineMyocardial infarctionMesenchymal stem cellHeart failureCell therapyEmbryonic stem cellreview